MannKind Corporation (Nasdaq:MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at the 29th Annual
Canaccord Adams Global Growth Conference on Wednesday, August 12,
2009 at 1:00 PM (EDT) at the InterContinental Hotel in Boston,
Massachusetts.
Interested parties can access a link to the live webcast of the
presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.
Replays of the presentations will be available for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development
and commercialization of therapeutic products for patients with diseases
such as diabetes and cancer. Its pipeline includes AFRESA®, MKC253,
MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA
requesting approval of AFRESA for the treatment of adults with type 1 or
type 2 diabetes for the control of hyperglycemia. Its other programs are
currently in Phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com
to which MannKind regularly posts copies of its press releases as well
as additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its reports
with the Securities and Exchange Commission or posts certain other
information to the website.
MannKind Corporation
Matthew J. Pfeffer
Corporate Vice
President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com
